Company Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 15:35:44 03/05/2024 BST			5-day change	1st Jan Change
3.03 ^USD	+0.66%		+11.69%	+131.72%

03-20	Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024
03-20	Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.

Number of employees: 25

Managers	Title	Age	Since
Jennifer Good FOU	Founder	59	28/02/11
Thomas Sciascia FOU	Founder	70	31/12/10
Lisa Delfini DFI	Director of Finance/CFO	54	08/08/21
Danine Summers CTO	Chief Tech/Sci/R&D Officer	-	08/08/21
David J. Clark CTO	Chief Tech/Sci/R&D Officer	59	13/11/22
Katie McManus IRC	Investor Relations Contact	-	-
Katherine Takaki LAW	General Counsel	-	-
Farrell Simon PRN	Corporate Officer/Principal	42	31/01/23
Christopher Galletta AUD	Comptroller/Controller/Auditor	-	11/04/21

Members of the board	Title	Age	Since
Anne VanLent BRD	Director/Board Member	76	09/10/18
James Cassella BRD	Director/Board Member	69	12/02/20
Jennifer Good FOU	Founder	59	28/02/11
Dominick Colangelo BRD	Director/Board Member	60	28/06/20
Ed Mathers Mathers BRD	Director/Board Member	64	30/06/17
Michael Heffernan BRD	Director/Board Member	59	31/01/17
David Meeker CHM	Chairman	69	30/06/17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	68,960,167	68,077,718 ( 98.72 %)	0	98.72 %

Name	Equities	%	Valuation
NEA Management Co. LLC 16.49 %	11,370,376	16.49 %	39 M $
Frazier Life Sciences Management LP 10.70 %	7,381,090	10.70 %	25 M $
Rubric Capital Management LP 8.243 %	5,684,420	8.243 %	20 M $
Viking Global Investors LP 6.380 %	4,400,000	6.380 %	15 M $
Venrock Associates 4.963 %	3,422,397	4.963 %	12 M $
Opaleye Management, Inc. 3.676 %	2,535,000	3.676 %	9 M $
Vanguard Fiduciary Trust Co. 3.253 %	2,243,399	3.253 %	8 M $
BlackRock Advisors LLC 3.191 %	2,200,421	3.191 %	8 M $
Checkpoint Capital LP 1.874 %	1,292,316	1.874 %	4 M $
MAI Capital Management LLC 1.855 %	1,279,458	1.855 %	4 M $

Trevi Therapeutics, Inc.

195 Church Street 14th floor

06510, New Haven

http://www.trevitherapeutics.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.01 USD

Average target price

7.4 USD

Spread / Average Target

+145.85%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
TREVI THERAPEUTICS, INC.	+131.72%	212M
VERTEX PHARMACEUTICALS INCORPORATED	-1.61%	103B
REGENERON PHARMACEUTICALS, INC.	+7.13%	101B
ARGENX SE	+4.13%	23.07B
BIONTECH SE	-13.15%	22.23B
GENMAB A/S	-5.15%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.94%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+7.00%	14.07B
SAREPTA THERAPEUTICS, INC.	+37.00%	12.35B

Bio Therapeutic Drugs